Hereditary peripheral neuropathy
Meaningful results through an integrated approach
Mayo Clinic Laboratories’ hereditary neuropathy testing is backed by a multidisciplinary team of clinical peripheral neuropathy experts, laboratory scientists, and genetic counselors to provide the highest standard for variant detection.
Using NGS techniques and unique interpretive reporting methods, our approach allows for optimal variant detection. This process reduces the risk of false negative results compared to whole exome sequencing and other capture techniques, providing physicians with confidence that disease-specific variants were not missed.
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to share industry updates and Mayo Clinic’s test development success in 2025. Later, Dr. Pritt welcomes Janelle Santos, M.D., a maternal-fetal medicine specialist at Mayo Clinic, to discuss how she uses a preeclampsia test to care for her patients.
Christopher Klein, M.D., discusses Mayo Clinic’s updated myasthenia gravis and Lambert-Eaton syndrome testing approach. Automatic reflex to second-line testing saves time and increases sensitivity and specificity to confirm diagnosis in patients with atypical presentation.
References
- Klein, C., Charcot-Marie-Tooth Disease and Other Hereditary Neuropathies. American Academy of Neurology. October 2020.